Condition: Migraine With Aura · Sponsor: Centre Hospitalier Universitaire de Nice
Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French headache centers.
This description comes directly from the study's public registry record.
Michel LANTERI-MINET, Dr · 04 92 03 76 46 · lanteri-minet.m@chu-nice.fr
sylvie ROMETTINO · romettino.s@chu-nice.fr
Always discuss trial participation with your own doctor first.
| Hôpital Pierre Wertheimer | Bron, France | Not Yet Recruiting |
| CHU Gabriel Montpied | Clermont-Ferrand, France | Not Yet Recruiting |
| AP-HM | Marly, France | Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| CHU de NICE | Nice, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04063540